On November 18, 2020 AbCellera, a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease, reported it has acquired Trianni, Inc. in an all-cash transaction valued at US$90 million (Press release, AbCellera, NOV 18, 2020, View Source [SID1234571365]). The acquisition deepens AbCellera’s technology stack with a suite of genetically engineered mice for generating diverse panels of human antibodies with drug-like properties.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Trianni marks our fourth and largest strategic technology addition to date. With its technology and team, Trianni amplifies our capability to generate human antibodies and provides a strong foundation for developing increasingly powerful transgenic mouse technologies," said Carl Hansen, Ph.D., CEO of AbCellera. "Trianni adds a key pillar to our platform, which now includes genetically engineered rodents, microfluidic single-cell screening, repertoire sequencing, AI-powered computation, and bispecific protein engineering. By integrating these technologies, we aim to provide our partners with access to a modern operating system that improves the speed and probability of success of antibody drug development."
Trianni’s genetic engineering technology is a platform for developing humanized mice. The flagship Trianni Mouse was designed to maximize immune responses, increase antibody diversity, and preserve natural maturation of fully human antibodies in rodents. The Trianni Mouse is also a core platform that supports the rapid development of new mouse strains tailored to address the most challenging antibody discovery programs. Several next-generation humanized mice are currently being developed and when launched aim to provide partners with the following benefits:
Generate multispecific antibodies and access difficult targets with the Heavy-Chain Only (HCO) Mouse, which expresses smaller, single domain antibodies that can reach target sites conventional IgG molecules cannot. HCO antibodies are ideally suited for applications in cell therapy and for bispecific and multispecific antibody therapeutics.
Break immune tolerance with the All-Epitope Mouse, which generates robust immune responses against highly-conserved, high-value drug targets such as GPCRs and ion channels that are prevalent in multiple diseases and indications, including cardiovascular diseases, cancer, neurological diseases, inflammation, and pain.
Target new epitopes with the DD Mouse, which has long CDR3 loops that can access "hidden" or recessed binding sites that are unreachable by conventional IgG molecules.
Maximize efficiency with the Eazysort Mouse, which allows up-front enrichment of immune cells that recognize the target to focus discovery efforts on only high-value antibodies of interest.